title: [Guidelines for the follow-up of women treated for high-grade cervical neoplasia].
abstract: The women treated for CIN2-3 remain at a substantially increased risk of recurrences, which persists longer than 10 years. The women treated for a CIN2-3 are more likely to develop invasive cancer and the risk is two to five times greater than that of the general population. The main objective of the follow-up of patients treated for high-grade CIN is in one hand, to detect and treat the recurrences and on the other hand, to determine a subpopulation presenting a high risk of recurrence which should be followed-up more intensively. At present, frequent follow-up with cytology and colposcopic evaluation of the cervix is the preferred strategy recommended in France by Anaes. Both, the cytology and the colposcopy don't have a very good sensitivity. HPV test is more sensitive compared to cytology or colposcopy in detecting CIN treatment failures. It would be more prudent to use a strategy involving both the cytology and HPV test. Both the sensitivity and the negative predictive value of combined cytology and HPV testing in detecting a residual disease or recurrence are around 100%. Women presenting negative results of both tests, could, then be considered at a low risk of recurrence and their surveillance should be the same as that of the screening of the general population. In case of positivity a more intensive follow-up should be organized.
authors.affiliation: Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, Paris, France. jlmergui@wanadoo.fr
authors.forename: J-L
authors.initials: JL
authors.lastname: Mergui
authors.forename: V
authors.initials: V
authors.lastname: Polena
authors.forename: E
authors.initials: E
authors.lastname: David-Montefiore
authors.forename: S
authors.initials: S
authors.lastname: Uzan
mesh_terms: D000367:Age Factors; D002584:Cervix Uteri / Q000473:pathology / Q000821:virology; D003127:Colposcopy; D003581:Cytodiagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D027383:Papillomaviridae / Q000302:isolation & purification; D010298:Parity; D011247:Pregnancy; D012307:Risk Factors; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000601:surgery / Q000628:therapy*